Abstract
BackgroundThe proteasome inhibitor bortezomib, approved for the treatment of multiple myeloma, has been demonstrated to deplete short- and long-lived plasma cells (PCs) and ameliorate nephritis in murine models of systemic...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have